Kwang Dong signs a Korean exclusive license agreement of female sexual desire disorder treatment
Kwang Dong Pharmaceutical(CEO Sung-Won Choi) announced on the 22nd that it signed a Korean exclusive license agreement of ‘bremelanotide,’ a substance candidate of novel drug developed by U.S. Palatin Technologies for the treatment of sexual desire disorder.
According to Kwang Dong Pharmaceutica...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
